Signaling Pathway For Possible Target For Cancer Treatment Identified: NYU Langone

In a new study published in the August 16th issue of Developmental Cell, researchers at NYU Langone Medical Center identified a molecular mechanism that guarantees

In a new study published in the August 16th issue of Developmental Cell, researchers at NYU Langone Medical Center identified a molecular mechanism that guarantees that new blood vessels form in the right place and with the proper abundance.

"We have known for a long time that blood vessels branch to give rise to new ones and that in some places of our bodies this branching occurs with a reproducible pattern. However, the mechanisms that ensure that new vessels sprout at specific locations had not been uncovered until now," said Jesús Torres-Vázquez, PhD, assistant professor of Developmental Genetics at the Skirball Institute of Biomolecular Medicine at NYU School of Medicine. "Our study illuminates the genetic basis behind the reproducible pattern of the vasculature and suggests ways in which the formation of new blood vessels could be modulated to treat certain cancers in the future."

Study Says Thyroid Cancer Treatment Varies by Hospital
Hospital factors play a key role in use of radioactive iodine treatment, finds study from the University of Michigan Comprehensive Cancer Center finds.

Using the zebrafish embryo as a model system, researchers identified that Semaphorin-PlexinD1 signaling limits the formation of new blood vessels. This signaling pathway works by ensuring that blood vessels make the proper levels of soluble Flt1. Soluble Flt1 is an inhibitor of the Vascular Endothelial Growth Factor (VEGF) pathway, which promotes the growth of new blood vessels.

These findings have broad implications for human health, since changes in the level of soluble Flt1 are associated with cancer, vascular birth defects and pregnancy-related hypertension (preeclampsia).

Gold In Cancer Treatment
Advanced imaging techniques might make gold useful in cancer treatment. They allow scientists to see where gold complexes used in potential chemotherapeutic treatments end up in cells.

According to researchers, the Semaphorin-PlexinD1 signaling pathway shows significant promise as a future therapeutic target for cancer treatment to slow the progression of diseases by controlling the blood vessel growth.

Source-Eurekalert

New Breast Cancer Treatment
An alternative therapy is recommended for patients with HER2-positive breast cancer when they develop resistance to trastuzumab, shows finding published in Clinical Cancer Research.